“The R&D is progressing smoothly and the project is steadily advancing. The product line has rapidly expanded from the initial single drug to a drug with many global patents.†Recently, in the Qingdao International Academician Port, Yan Yi, the principal of the Wang Yutian academician team introduced the current development progress. The fast-paced broad-spectrum detoxification drug PMS-001 can not only treat opioid traditional drugs such as morphine and heroin addiction, but also can treat drug addiction such as methamphetamine and ecstasy, and can theoretically be used for the treatment of gambling and internet addiction. .
According to Dong Mingxin, R&D director of the Academician team, there is no drug available on the market for new drug addiction. Therefore, PMS-001 has a broad market prospect and important social effects. According to preliminary calculations, the domestic market for drug addiction has exceeded 10 billion yuan. After the successful listing of PMS-001, the PMS-001 will be advanced to Phase I clinical trials. Phase II clinical trials of PMS-001 were completed within four years. Phase III clinical trials of PMS-001 were completed within six years to promote the successful marketing of the drug. Apart from broad-spectrum drug addiction treatment, the academician team focused on major diseases of the nervous system such as Alzheimer's disease, stroke and schizophrenia. The research project also included PMS-002 (small molecule modulators of NMDA receptors) for the treatment of stroke. PMS-003 (Indip Peptide) for the treatment of acne, obesity and oil control cosmetics, etc., is dedicated to the development and industrialization of peptides and small molecule drugs.
According to reports, the new drug R&D center of Academician Wang Yutian of the Royal Academy of Sciences in Canada was officially opened in March 2017 at the Qingdao International Academician Port. Academician Wang Yutian is an internationally renowned neurobiologist, a tenured professor at the University of British Columbia in Canada, and a chief researcher of cerebral apoplexy in British Columbia and Yukon. He has twice been selected as an international researcher at the Howard Hughes Medical Institute in the United States. Top journals such as "Nature" and "Cell" published their dozens of high-level papers by their first author and correspondent author.
Wang Yutian is not only engaged in basic theoretical research, but also committed to the application of breakthroughs in theoretical research to clinical medical practice, especially for learning and memory disorders and central nervous system diseases such as stroke, epilepsy, and drug addiction, obtained in the development of specific drugs. A series of internationally leading achievements, with a number of internationally protected drug patents and new technology patents that can be used for drug development. Years of basic scientific research and drug development experience have enabled academician Wang Yutian to have a wealth of experience in the field of scientific research transformation.
Wang Yutian deeply sighed: “In Qingdao International Academician Harbor, we have gathered a team of highly-advanced academicians from different disciplines at home and abroad. Teams of academicians from different disciplines can easily shed new light on the spark of innovation in order to maintain our constant innovation. This is the primary driving force for us to settle in.†At the same time, the all-round support and services provided by the Liberian and Academician Ports to the academician team not only provide resources and opportunities for academicians to start their own businesses, but also provide a comfortable office environment and top aspects of life. The service can really allow academicians to bury their heads in business and have no worries. (Correspondent Xu Mengting Zhao Qian)
China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.apipepdites.com